Pharmacogenetics of alcohol use disorder treatments: an update

References

• Center for Behavioral Health Statistics and Quality. Results from the. 2016. National survey on drug use and health: detailed tables. [Cited 2018 Oct 15]. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf
   Google Scholar
• Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72(8):757–766.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2016 national survey on drug use and health. In: Center for behavioral health statistics and quality. Rockville; 2017. Available from: https://www.samhsa.gov/data/
   Google Scholar
• American Psychological Association. Diagnostic and statistical manual 5th. Arlington, VA: The American Psychiatric Association is the publisher; 2013.
   Google Scholar
• Han C, McGue MK, Iacono WG. Lifetime tobacco, alcohol and other substance use in adolescent Minnesota twins: univariate and multivariate behavioral genetic analyses. Addiction. 1999;94(7):981–993.
   Google Scholar
• Verhulst B, Neale MC, Kendler KS. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. Psychol Med. 2015;45(5):1061–1072.
   Google Scholar
• Tawa EA, Hall SD, Lohoff FW. Overview of the genetics of alcohol use disorder. Alcohol Alcohol. 2016;51(5):507–514.
   Google Scholar
• Dick DM, Kendler KS. The impact of gene-environment interaction on alcohol use disorders. Alcohol Res. 2012;34(3):318–324.
   Google Scholar
• Salvatore JE, Gottesman II, Dick DM. Endophenotypes for alcohol use disorder: an update on the field. Curr Addict Rep. 2015;2(1):76–90.
   Google Scholar
• Jones JD, Comer SD, Kranzler HR. The pharmacogenetics of alcohol use disorder. Alcohol Clin Exp Res. 2015;39(3):391–402.
   Google Scholar
• Chastain G. Alcohol, neurotransmitter systems, and behavior. J Gen Psychology. 2006;133(4):329–335.
   Google Scholar
• Campbell AD, Kohl RR, McBride WJ. Serotonin-3 receptor and ethanol-stimulated somatodendritic dopamine release. Alcohol. 1996;13(6):569–574.
   Google Scholar
• Mark TL, Kassed CA, Vandivort-Warren R, et al. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1–3):345–349.
   Google Scholar
• Oliva EM, Maisel NC, Gordon AJ, et al. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374.
   Google Scholar
• Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36(6):584–589.
   Google Scholar
• Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA-J Am Med Assoc. 2018;320(8):815–824.
   Google Scholar
• Soyka M, Müller CA. Pharmacotherapy of alcoholism – an update on approved and off-label medications. Expert Opin Pharmaco. 2017;18(12):1187–1199.
   Google Scholar
• van Den Brink W, Sorensen P, Torup L, et al. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study. J Psychopharmacol. 2014;28(8):733–744.
   Google Scholar
• Mann K, Bladstrom A, Torup L, et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706–713.
   Google Scholar
• Gual A, He Y, Torup L, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11):1432–1442.
   Google Scholar
• Agabio R, Leggio L. Baclofen in the treatment of patients with alcohol use disorder and other mental health disorders. Front Psychiatry. 2018;9:464–471.
   Google Scholar
• Walker LC, Lawrence AJ. Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders. Expert Opin Inv Drug. 2018;27(8):677–690.
   Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. Jama. 2006;295(17):2003–2017.
   Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. Jama. 2014;311(18):1889–1900.
   Google Scholar
• Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275–293.
   Google Scholar
• Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. New Engl J Med. 2001;345(24):1734–1739.
   Google Scholar
• Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics. 2013;14(7):813–824.
   Google Scholar
• Mague SD, Blendy JA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend. 2010;108(3):172–182.
   Google Scholar
• Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacol. 2003;28(8):1546–1552.
   Google Scholar
• Pettinati HM, Anton RF, Willenbring ML. The combine study: an overview of the largest pharmacotherapy study to date for treating alcohol dependence. Psychiatr. 2006;3(10):36–39.
   Google Scholar
• Anton RF, Oroszi G, O’Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65(2):135–144.
   Google Scholar
• Gelernter J, Gueorguieva R, Kranzler HR, et al. Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) variants and response to Naltrexone treatment for alcohol dependence: results From the VA cooperative study. Alcohol Clin Exp Res. 2007;31(4):555–563.
   Google Scholar
• Arias AJ, Gelernter J, Gueorguieva R, et al. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. Am J Addict. 2014;23(3):288–293.
   Google Scholar
• Cubells J, Zabetian C. Human genetics of plasma dopamine β-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacol. 2004;174(4):463–476.
   Google Scholar
• Foulds JA, Ton K, Kennedy MA, et al. OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients. Pharmacogenet Genomics. 2015;25(5):270–273.
   Google Scholar
• Oslin DW, Leong SH, Lynch KG, et al. Naltrexone vs placebo for the treatment of alcohol dependence: A randomized clinical trial. JAMA Psychiatry. 2015;72(5):430–437.
   Google Scholar
• Schacht JP, Randall PK, Latham PK, et al. Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status. Neuropsychopharmacol. 2017;42:2640–2653.
   Google Scholar
• Coller JK, Cahill S, Edmonds C, et al. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet Genomics. 2011;21(12):902–905.
   Google Scholar
• Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the μ-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83(3):262–268.
   Google Scholar
• Hernandez-Avila CA, Covault J, Wand G, et al. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics. 2007;17(12):1031–1038.
   Google Scholar
• Kim S-G, Kim C-M, Choi S-W, et al. A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacolog. 2009;201(4):611–618.
   Google Scholar
• Ray LA, Bujarski S, Chin PF, et al. Pharmacogenetics of naltrexone in Asian Americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacol. 2012;37(2):445–455.
   Google Scholar
• Ray LA, Green R, Roche DJO, et al. Pharmacogenetic effects of naltrexone in individuals of East Asian descent: human laboratory findings from a randomized trial. Alcohol Clin Exp Res. 2018;42(3):613–623.
   Google Scholar
• Cservenka A, Yardley MM, Ray LA. Review: pharmacogenetics of alcoholism treatment: implications of ethnic diversity. Am J Addict. 2017;26(5):516–525.
   Google Scholar
• Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9):1069–1077.
   Google Scholar
• Ashenhurst JR, Bujarski S, Ray LA. Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacol Biochem Behav. 2012;103(2):253–259.
   Google Scholar
• Crist R, Ambrose-Lanci L, Vaswani M, et al. Case–control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend. 2013;127(1–3):122–128.
   Google Scholar
• Nelson EC, Lynskey MT, Heath AC, et al. Association of OPRD1 polymorphisms with heroin dependence in a large case‐control series. Addict Biol. 2014;19(1):111–121.
   Google Scholar
• Zhang H, Kranzler H, Yang B, et al. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry. 2008;13(5):531.
   Google Scholar
• Setiawan E, Pihl RO, Cox SML, et al. The effect of naltrexone on alcohol’s stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res. 2011;35(6):1134–1141.
   Google Scholar
• Hutchison KE, Allen DL, Filbey FM, et al. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry. 2007;64(9):1078–1086.
   Google Scholar
• McGeary JE, Monti PM, Rohsenow DJ, et al. Genetic moderators of naltrexone’s effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006;30(8):1288–1296.
   Google Scholar
• Caye A, Spadini AV, Karam RG, et al. Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry. 2016;25(11):1151–1159.
   Google Scholar
• McGeary J. The DRD4 exon 3 VNTR polymorphism and addiction-related phenotypes: a review. Pharmacol Biochem Behav. 2009;93:222–229.
   Google Scholar
• Lai JH, Zhu YS, Huo ZH, et al. Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction. Brain Res. 2010;1359:227–232.
   Google Scholar
• Schmidt LA, Fox NA, Perez-Edgar K, et al. Linking gene, brain, and behavior: DRD4, frontal asymmetry, and temperament. Psychol Sci. 2009;20:831–837.
   Google Scholar
• Chamorro AJ, Marcos M, Mirón‐Canelo JA, et al. Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis. Addict Biol. 2012;17(3):505–512.
   Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis. Pharmacogenomics. 2014;15(13):1687–1700.
   Google Scholar
• Schacht JP, Anton RF, Voronin KE, et al. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacol. 2013;38(3):414–422.
   Google Scholar
• Ziauddeen H, Nestor LJ, Subramaniam N, et al. Opioid antagonists and the A118G polymorphism in the μ-opioid receptor gene: effects of GSK1521498 and naltrexone in healthy drinkers stratified by OPRM1 genotype. Neuropsychopharmacolo. 2016;41:2647–2657.
   Google Scholar
• Boettiger CA, Kelley EA, Mitchell JM, et al. Now or later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. Pharmacol Biochem Behav. 2009;93(3):291–299.
   Google Scholar
• Yoshimura A, Kimura M, Nakayama H, et al. Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. Alcohol Clin Exp Res. 2014;38(2):572–578.
   Google Scholar
• Gross ER, Zambelli VO, Small BA, et al.. A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2*2 variant. Ann Rev Pharmacol. 2015;55:107–127.
   Google Scholar
• Thompson A, Owens L, Pushpakom SP, et al. Pharmacotherapy for alcohol dependence: a stratified approach. Pharmacol Therapeut. 2015;153:10–24.
   Google Scholar
• Ooteman W, Naassila M, Koeter MWJ, et al. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009;14(3):328–337.
   Google Scholar
• Karpyak V, Biernacka J, Geske J, et al. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry. 2014;4(10):e453.
   Google Scholar
• Kiefer F, Witt S, Frank J, et al. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J. 2011;11(5):368–374.
   Google Scholar
• Karpyak VM, Winham SJ, Biernacka JM, et al. Association of GATA4 sequence variation with alcohol dependence. Addict Biol. 2014;19(2):312–315.
   Google Scholar
• Soyka M. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmaco. 2016;17(4):619–626.
   Google Scholar
• Palpacuer C, Laviolle B, Boussageon R, et al. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and neta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12(12):e1001924.
   Google Scholar
• Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res. 2007;31(7):1179–1187.
   Google Scholar
• Arias AJ, Armeli S, Gelernter J, et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008;32(7):1159–1166.
   Google Scholar
• Blodgett JC, Del Re AC, Maisel NC, et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481–1488.
   Google Scholar
• Skradski S, White HS. Topiramate blocks kainate‐evoked cobalt influx into cultured neurons. Epilepsia. 2000;41:45–47.
   Google Scholar
• Gibbs III JW, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: blockade of kainate‐evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41:10–16.
   Google Scholar
• Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. Jama. 2007;298(14):1641–1651.
   Google Scholar
• Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677–1685.
   Google Scholar
• Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003;23:7069–7074.
   Google Scholar
• Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacol. 2004;46:1097–1104.
   Google Scholar
• Sampaio AS, Fagerness J, Crane J, et al. Association between polymorphisms in GRIK2 gene and obsessive-compulsive disorder: a family-based study. CNS Neurosci Ther. 2011;17:141–147.
   Google Scholar
• Hirata Y, Zai CC, Souza RP, et al. Association study of GRIK1 gene polymorphisms in schizophrenia: case–control and family-based studies. Hum Psychopharmacol Clin. 2012;27:345–351.
   Google Scholar
• Lee J-H, Lee J-M, Ramos EM, et al. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington’s disease. Biochem Biophys Res Commun. 2012;424(3):404–408.
   Google Scholar
• Kranzler HR, Gelernter J, Anton RF, et al. Association of markers in the 3ʹ region of the GluR5 kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res. 2009;33(5):925–930.
   Google Scholar
• Ray LA, Miranda R, MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17(2):122–129.
   Google Scholar
• Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445–452.
   Google Scholar
• Feinn R, Curtis B, Kranzler HR. Balancing Risk and Benefit in heavy drinkers treated with topiramate: implications for personalized care. J Clin Psychiatry. 2016;77(3):e278–e282.
   Google Scholar
• Kranzler HR, Wetherill R, Feinn R, et al. Posttreatment effects of topiramate treatment for heavy drinking. Alcohol Clin Exp Res. 2014;38(12):3017–3023.
   Google Scholar
• Morley KC, Kranzler HR, Luquin N, et al. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials. 2018;19(1):443.
   Google Scholar
• Kranzler HR, Armeli S, Tennen H, et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol. 2011;31(1):22–30.
   Google Scholar
• Sachs BD, Dodson K. Chapter 18 - Serotonin deficiency and alcohol use disorders. In: Watson RR, Zibadi S, editors. Addictive substances and neurological disease. London, UK: Academic Press; 2017. p. 181–189.
   Google Scholar
• Kenna GA, Zywiak WH, Swift RM, et al. Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings. Alcohol. 2014 Sep;48(6):515–522.
   Google Scholar
• Schadé A, Marquenie LA, van Balkom AJLM, et al. The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. Alcohol Clin Exp Res. 2005;29:794–800.
   Google Scholar
• Pettinati HM, Volpicelli JR, Luck G, et al. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol. 2001;21:143–153.
   Google Scholar
• Rossinfosse C, Wauthy J, Bertrand J. SSRI antidepressants and alcoholism. Rev Med Liege. 2000;55:1003–1010.
   Google Scholar
• Kenna GA. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des. 2010;16(19):2126–2135.
   Google Scholar
• Ait-Daoud N, Seneviratne C, Smith JB, et al. Preliminary evidence for cue-induced alcohol craving modulated by serotonin transporter gene polymorphism rs1042173. Front Psychiatry. 2012;3:6–11.
   Google Scholar
• Kang H-J, Kim J-M, Stewart R, et al. Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. Prog Neuro-Psychopharmacol. 2013;44:23–28.
   Google Scholar
• Koenen KC, Uddin M, Chang S-C, et al. SLC6A4 methylation modifies the effect of the number of traumatic events on risk for posttraumatic stress disorder. Depress Anxiety. 2011;28(8):639–647.
   Google Scholar
• Goldman N, Glei DA, Lin Y-H, et al. The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms. Depress Anxiety. 2010;27(3):260–269.
   Google Scholar
• Strug LJ, Suresh R, Fyer AJ, et al. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). Mol Psychiatry. 2008;15:166.
   Google Scholar
• Bauer IE, Graham DP, Soares JC, et al. Serotonergic gene variation in substance use pharmacotherapy: a systematic review. Pharmacogenomics. 2015;16(11):1–8.
   Google Scholar
• Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol. 1989 1989;25(Suppl 1):S21–S4. discussion S25–7.
   Google Scholar
• Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011;168(3):265–275.
   Google Scholar
• Johnson BA, Seneviratne C, Wang X-Q, et al. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT3 antagonist ondansetron. Am J Psychiatry. 2013;170(9):1020–1031.
   Google Scholar
• Kenna GA, Zywiak WH, Swift RM, et al. Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5ʹ-HTTLPR genotype: a laboratory study. Alcohol Clin Exp Res. 2014;38(6):1567–1574.
   Google Scholar
• Agabio R, Sinclair JMA, Addolorato G, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatr, 2018;5(12):957-960.
   Google Scholar
• Morley KC, Luquin N, Baillie A, et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction. 2018;113(12):2205–2213.
   Google Scholar
• Vlachou S, Markou A. GABAB receptors in reward processes. In: Blackburn TP, editor. Advances in pharmacology. Vol. 58. London, UK: Academic Press; 2010. p. 315–371.
   Google Scholar
• Fatemi SH, Folsom TD, Thuras PD. Deficits in GABAB receptor system in schizophrenia and mood disorders: A postmortem study. Schizophr Res. 2011;128(1):37–43.
   Google Scholar
• Heaney CF, Kinney JW. Role of GABAB receptors in learning and memory and neurological disorders. Neurosci Biobehav R. 2016;63:1–28.
   Google Scholar
• D’Souza MS, Markou A. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sc Clin Pract. 2011;6(1):4–16.
   Google Scholar
• Palpacuer C, Duprez R, Huneau A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018 Feb;113(2):220–237.
   Google Scholar
• Ray LA, Bujarski S, Yardley MM, et al. Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter? Am J Drug Alcohol Abuse. 2017;43(6):703–710.
   Google Scholar
• Rohn MC, Lee MR, Kleuter SB, et al. Differences between treatment‐seeking and nontreatment‐seeking alcohol‐dependent research participants: an exploratory analysis. Alcohol Clin Exp Res. 2017;41(2):414–420.
   Google Scholar
• Oliver JA, McClernon FJ. Precision medicine in addiction research: where has the time gone? Addiction. 2017;112(12):2096–2097.
   Google Scholar
• Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl. 2005;s15:170–178.
   Google Scholar
• Miller PM, Book SW, Stewart SH. Medical treatment of alcohol dependence: a systematic review. Int J Psychiatry Med. 2011;42(3):227–266.
   Google Scholar
• van der Stel J. Precision in addiction care: does it make a difference? Yale J Biol Med. 2015;88(4):415–422.
   Google Scholar
• Baurley JW, McMahan CS, Ervin CM, et al. Biosignature discovery for substance use disorders using statistical learning. Trends Mol Med. 2018;24(2):221–235.
   Google Scholar
• Witkiewitz K, Kranzler HR, Hallgren KA, et al. Drinking risk level reductions associated with improvements in physical health and quality of life among individuals with alcohol use disorder. Alcohol Clin Exp Res. 2018;42(12):2453–2465.
   Google Scholar
• Roche DJ, Ray LA. Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. Pharmacogenomics. 2015;16(7):721–736.
   Google Scholar
• Mann K, Roos CR, Hoffmann S, et al. Precision medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes. Neuropsychopharmacolog. 2017;43:891–899.
   Google Scholar
• Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med. 2015;21(5):285–294.
   Google Scholar
• Colagiuri B, Schenk LA, Kessler MD, et al. The placebo effect: from concepts to genes. Neuroscience. 2015;307:171–190.
   Google Scholar
• Ray LA, Barr CS, Blendy JA, et al. The role of the Asn40Asp polymorphism of the nu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res. 2012;36(3):385–394.
   Google Scholar
• Hart AB, Kranzler HR. Alcohol dependence genetics: lessons learned from genome-Wide association studies (GWAS) and post-GWAS analyses. Alcohol Clin Exp Res. 2015;39(8):1312–1327.
   Google Scholar
• Gelernter J, Kranzler HR, Sherva R, et al. Genome-wide association study of alcohol dependence: significantfindings in African- and European-Americans including novel risk loci. Mol Psychiatry. 2013;19:41–49.
   Google Scholar
• Walters RK, Adams MJ, Adkins AE, et al. Trans-ancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. bioRxiv. 2018: 257311 (preprint).
   Google Scholar
• Seneviratne C, Johnson BA. Advances in medications and tailoring treatment for alcohol use disorder. Alcohol Res Curr Rev. 2015;37(1):15–28.
   Google Scholar
• Kranzler HR, Smith RV, Schnoll R, et al. Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not? Addiction. 2017;112(12):2086–2094.
   Google Scholar
• Ikediobi ON. Somatic pharmacogenomics in cancer. Pharmacogenomics J. 2008;8:305.
   Google Scholar
• Williams EC, Young JP, Achtmeyer CE, et al. Primary care providers’ interest in using a genetic test to guide alcohol use disorder treatment. J Subst Abuse Treat. 2016;70:14–20.
   Google Scholar
• Gaziano JM, Concato J, Brophy M, et al. Million veteran program: a mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214–223.
   Google Scholar
• Allen N, Sudlow C, Downey P, et al. UK biobank: current status and what it means for epidemiology. Health Policy Technol. 2012;1(3):123–126.
   Google Scholar
• Roden D, Denny J. Integrating electronic health record genotype and phenotype datasets to transform patient care. Clin Pharmacol Ther. 2016;99(3):298–305.
   Google Scholar
• Clarke TK, Adams MJ, Davies G, et al. Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK biobank (N=112 117). Mol Psychiatry. 2017;22:1376.
   Google Scholar